Gilead Sciences Inc.’s net income fell in the first quarter as much-lower sales of the flu medication Tamiflu caused its royalty revenue to plummet, wiping out modest gains in other areas.
Popular Posts:
- Aetna 3Q profit jumps 53 percent on lower costs
- Mindray Medical posts lower profit in 3Q
- Aetna 3Q profit jumps 53 percent on lower costs
- Dendreon takes bigger 3Q loss, Provenge sales rise
- Summary Box: Pfizer sales, profit just beat views